clovomet metoclopramide hydrochloride 10 mg film coated tablets bottle
ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation
ipca-metoclopramide metoclopramide hydrochloride 10 mg film coated tablets bottle
ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation
metpram metoclopramide hydrochloride 10 mg film coated tablets bottle
ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation
pca-metoclopramide metoclopramide hydrochloride 10 mg film coated tablets bottle
gm pharma international pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation
perinorm metoclopramide hydrochloride 10 mg film coated tablets bottle
ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation
ipca-metoclopramide metoclopramide hydrochloride 10 mg film coated tablets blister pack
ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation
metoclopramide hydrochloride tablet
redpharm drug, inc. - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide tablets, usp is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux: metoclopramide tablets, usp are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic gas
metoclopramide tablet
ncs healthcare of ky, inc dba vangard labs - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux: metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic gastroparesis
metoclopramide tablet
nucare pharmaceuticals,inc. - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux: metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic gastroparesis
metoclopramide hydrochloride oral solution 5mg/5ml
syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - metoclopramide hydrochloride - oral solution - metoclopramide hydrochloride 5 mg/5ml - drugs for functional gastrointestinal disorders